These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7913085)

  • 21. Mitotic activity and prognosis in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Prostate; 1995 Feb; 26(2):80-6. PubMed ID: 7855001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
    Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
    Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
    Kallakury BV; Sheehan CE; Rhee SJ; Fisher HA; Kaufman RP; Rifkin MD; Ross JS
    Cancer; 1999 Apr; 85(7):1569-76. PubMed ID: 10193948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer.
    Setälä L; Kosma VM; Lipponen P; Naukkarinen A; Nordling S; Hollmén S; Eskelinen M; Syrjänen K; Alhava E
    J Cancer Res Clin Oncol; 1998; 124(9):497-502. PubMed ID: 9808424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer.
    Aaltomaa S; Lipponen P; Vesalainen S; Ala-Opas M; Eskelinen M; Syrjänen K
    Eur Urol; 1997; 32(4):410-5. PubMed ID: 9412797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung.
    Demarchi LM; Reis MM; Palomino SA; Farhat C; Takagaki TY; Beyruti R; Saldiva PH; Capelozzi VL
    Mod Pathol; 2000 May; 13(5):511-20. PubMed ID: 10824922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
    Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
    Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The expression of proliferating cell nuclear antigen (PCNA) immunostaining in renal pelvic and ureteral cancers and its prognostic value].
    Kamijo T; Sato T; Yanagizawa R; Kishi H
    Nihon Hinyokika Gakkai Zasshi; 1994 Jun; 85(6):938-44. PubMed ID: 7914944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
    Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
    BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Alhava E; Syrjänen K
    Anticancer Res; 1994; 14(2B):709-14. PubMed ID: 8010731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining.
    Aaltomaa S; Lipponen P; Syrjänen K
    Anticancer Res; 1992; 12(4):1281-6. PubMed ID: 1380227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma.
    Visakorpi T
    J Pathol; 1992 Sep; 168(1):7-13. PubMed ID: 1360498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of proliferating cell nuclear antigen in node-negative human prostate cancer.
    Idikio HA
    Anticancer Res; 1996; 16(5A):2607-11. PubMed ID: 8917358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
    Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
    Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract.
    Lee CS
    Cancer; 1996 Nov; 78(9):1881-7. PubMed ID: 8909306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater.
    Ajiki T; Kamigaki T; Hasegawa Y; Fujino Y; Suzuki Y; Takeyama Y; Ku Y; Kuroda Y
    Hepatogastroenterology; 2001; 48(41):1266-70. PubMed ID: 11677943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.